Zidesamtinib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Zidesamtinib
- Molecular weight
- 419.46
- Structure (SMILES)
- CCn1ncc2c1-c1cnc(N)c(c1)O[C@H](C)c1cc(F)ccc1-c1nn(C)nc1C2
- jideytro
- JIDEYTRO
- nu 0002362
- nu 0002362 006
- nu 0002362 009
- nu 2362 010
- nu 520
- NU-0002362
- NU-0002362-006
- NU-0002362-009
- NU-2362-010
- NU-520
- nuv 520
- NUV-520
- nvl 520
- Nvl-520
- NVL-520
- zidesamtinib
- Zidesamtinib
- Zidesamtinib (NVL-520)
- Zidesamtinib [INN]
- Zidesamtinib [USAN]
- Zidesamtinib [WHO-DD]
- zidesamtinib inn
- zidesamtinib usan
And 1 more, listed on the interactive page.
- CAS registry numbers
- 2739829-00-4
- ChEMBL ID
- CHEMBL5314497
- InChIKey
- DTWUUAFTYSMNQX-GFCCVEGCSA-N
- PubChem compound IDs
- 166560233
- FDA ingredient codes (UNII)
- MX5KQV5XHC
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- Yes
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- zidesamtinib
- Type
- Synthetic organic
- Drug name stem
- -tinib
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- neurotrophic receptor tyrosine kinase 1
- Gene symbol
- NTRK1
- Protein identifier
- P04629
- Affinity units
- pKi
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- c-ros oncogene 1, receptor tyrosine kinase
- Gene symbol
- ROS1
- Protein identifier
- P08922
- Median affinity
- 9.15
- Affinity units
- pIC50
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- c-ros oncogene 1, receptor tyrosine kinase
- Gene symbol
- ROS1
- Protein identifier
- P08922
- Median affinity
- 7.3
- Affinity units
- pKi
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 1
Trial references
- NCT05118789
- Hydrogen bond acceptors
- 8
- Hydrogen bond donors
- 1
- Polar surface area
- 96.67
- Calculated partition coefficient (ALogP)
- 3.53
- Calculated partition coefficient (XLogP)
- 2.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 31
- Molecular formula
- C22H22FN7O
- Monoisotopic mass
- 419.18698651
- Natural product
- No
- 85001-101
- 85001-102
- Recorded assays
- 59
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (2)
- A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
In development for (2)
- Cancer Phase 2
- Neoplasm Phase 2